2-((1H-azol-1-yl)methyl)-N-arylbenzamides:: Novel dual inhibitors of VEGFR-1/2 kinases

被引：17

作者：

Kiselyov, AS

Semenova, M

Semenov, VV

Piatnitski, E

机构：

[1] Chem Divers Inc, Small Mol Drug Discovery, San Diego, CA 92121 USA

[2] Russian Acad Sci, Inst Dev Biol, Moscow 119334, Russia

[3] Russian Acad Sci, ND Zelinskii Organ Chem Inst, Moscow 117913, Russia

[4] ImClone Syst, Small Mol Drug Discovery, New York, NY 10014 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 06期

关键词：

vascular endothelial growth factor receptor 2; receptor tyrosine kinase; dual kinase inhibitor; angiogenesis; 2-((1H-azol-1-yl)methyl)-N-arylbenzyl amides;

D O I：

10.1016/j.bmcl.2005.11.105

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Novel potent derivatives of (azol-1-yl)methyl-N-arylbenzamides with improved solubility (>3 mM) are described as ATP-competitive inhibitors of vascular endothelial growth factor receptor 2 (VEGFR-2). Many compounds display VEGFR-2 inhibitory activity reaching IC50 < 100 nM in the enzymatic assay. The compounds also inhibit the related tyrosine kinase, VEGFR-1, with similar potencies. Several compounds containing bulky lipophilic substituents at the benzamide pharmacophore yielded 10- to 17-fold selectivity for the VEGFR-2 versus VEGFR-1 kinase. (C) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1726 / 1730

页数：5

共 18 条

[1] ALTMANN KH, 2005, Patent No. 6878720
[2] Berman H.M., 2000, Protein Data Bank, P235
[3] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
Bold, G
Altmann, KH
Frei, J
Lang, M
Manley, PW
Traxler, P
Wietfeld, B
Brüggen, J
Buchdunger, E
Cozens, R
Ferrari, S
Furet, P
Hofmann, F
Martiny-Baron, G
Mestan, J
Rösel, J
Sills, M
Stover, D
Acemoglu, F
Boss, E
Emmenegger, R
Lässer, L
Masso, E
Roth, R
Schlachter, C
Vetterli, W
Wyss, D
Wood, JM
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) : 2310 - 2323
[4] Antiangiogenic cancer therapy
Culy, C
[J]. DRUGS OF TODAY, 2005, 41 (01) : 23 - 36
[5] Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens, FALM
[J]. BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 1 - 7
[6] Pegaptanib sodium
Fine, SL
Martin, DF
Kirkpatrick, P
[J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) : 187 - 188
[7] ANGIOGENIC FACTORS
FOLKMAN, J
KLAGSBRUN, M
[J]. SCIENCE, 1987, 235 (4787) : 442 - 447
[8] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D
Folkman, J
[J]. CELL, 1996, 86 (03) : 353 - 364
[9] Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
Hennequin, LF
Stokes, ESE
Thomas, AP
Johnstone, C
Plé, PA
Ogilvie, DJ
Dukes, M
Wedge, SR
Kendrew, J
Curwen, JO
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) : 1300 - 1312
[10] Molecular angiogenesis
Klagsbrun, M
Moses, MA
[J]. CHEMISTRY & BIOLOGY, 1999, 6 (08): : R217 - R224

← 1 2 →